In general, caution should be exercised in the administration of 3TC in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.Efavirenz, Lamivudine and Tenofovir disoproxil fumarate is not recommended for patients with impaired renal function (i.e., creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis because it is a fixed-dose combination formulation that cannot be adjusted Efavirenz, Lamivudine and Tenofovir disoproxil fumarate is not recommended for patients with moderate or severe hepatic impairment because there are insufficient data to determine whether dose adjustment is necessary. More studies are warranted to elucidate the role of postmortem redistribution and to inform extrapolation from postmortem to antemortem exposures. However, drug interaction studies have been conducted with the individual components of Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets (EFV, 3TC, and TDF) Drug interactions with EFV are summarized in Table 5 [for pharmacokinetics data No dosage adjustment is recommended when Efavirenz, Lamivudine and Tenofovir disoproxil fumarate is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam.3TC, a component of Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets, is predominantly eliminated in the urine by active organic cationic secretion. Select one or more newsletters to continue. After 4 weeks of therapy, the prevalence of nervous system symptoms of at least moderate severity ranged from 5% to 9% in patients treated with regimens containing EFV and from 3% to 5% in patients treated with a control regimen. Dosage Form; Route: Tablet; oral . Tenofovir, lamivudine, and efavirenz concentrations were measured using liquid chromatography and tandem mass spectrometry in plasma and CSF from 14 individuals with HIV, 7 with cryptococcal meningitis. Subjects were randomized 1:1 to receive EFV 400 mg in combination with TDF 300 mg plus FTC 200 mg all given once daily or EFV 600 mg in combination with TDF 300 mg/FTC 200 mg given once daily. The mean increase at Week 48 from baseline in CD4Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets are supplied as fixed-dose combination tablets containing efavirenz USP 400 mg, lamivudine USP 300 mg and tenofovir disoproxil fumarate 300 mg equivalent to tenofovir disoproxil 245 mg. Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets are white to off-white, film-coated, oval, biconvex tablets debossed with “L40” on one side and plain on other side. Antiretrovirals differentially penetrate into the CNS and penetration may be enhanced by meningitis.Despite HIV therapy, persistent viral replication occurs in certain anatomic sites, and systemic viral rebound will occur within weeks of treatment interruption.Inflammation at the blood–CSF barrier or the CSF–brain barrier could lead to altered drug distribution via opening of tight junctions, altered pH changing drug ionization, and downregulation of efflux transporters.Postmortem drug quantification has been used in forensics for decades to assist with determining cause of death, in particular when overdose was suspected. Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg.Prior to initiation of Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets, test patients for hepatitis B virus infection It is recommended that serum creatinine, serum phosphorus, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets and during therapy in all patients as clinically appropriate Monitor hepatic function prior to and during treatment with Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets Efavirenz, Lamivudine and Tenofovir disoproxil fumarate tablets are a three-drug fixed-dose combination product containing 400 mg of efavirenz (EFV), 300 mg of lamivudine (3TC), and 300 mg of tenofovir disoproxil fumarate (TDF).